0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover89.10%IV-8.12%PremiumMay 16, 2025Expiry Date1.69Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6270Delta0.0991Gamma8.16Leverage Ratio-0.0455Theta-0.0059Rho-5.12Eff Leverage0.0163Vega
Travere Therapeutic Stock Discussion
Breakthrough: FILSPARI Secures Standard EU Approval as First DEARA Therapy for IgA Nephropathy
New Clinical Data: FILSPARI Achieves Faster Remission in FSGS and IgAN Patients
Breakthrough: First-Ever FSGS Treatment Could Get FDA Green Light - FILSPARI Shows Superior Results
Travere's FILSPARI Eyes Breakthrough: First-Ever Treatment for 40,000 FSGS Patients
Travere Therapeutic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.02%)
Someone buying large blocks 150k, 50k....
Does anybody know what's going on?
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address ...
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
No comment yet